These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29549643)

  • 1. Using High-Throughput Sequencing to Characterize the Development of the Antibody Repertoire During Infections: A Case Study of HIV-1.
    Breden F; Watson CT
    Adv Exp Med Biol; 2017; 1053():245-263. PubMed ID: 29549643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.
    Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J
    mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection.
    Setliff I; McDonnell WJ; Raju N; Bombardi RG; Murji AA; Scheepers C; Ziki R; Mynhardt C; Shepherd BE; Mamchak AA; Garrett N; Karim SA; Mallal SA; Crowe JE; Morris L; Georgiev IS
    Cell Host Microbe; 2018 Jun; 23(6):845-854.e6. PubMed ID: 29861170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development.
    Zhang Y; Yuan T; Li J; Zhang Y; Xu J; Shao Y; Chen Z; Zhang MY
    AIDS; 2013 Oct; 27(16):2529-39. PubMed ID: 24100711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection.
    Sheng Z; Schramm CA; Connors M; Morris L; Mascola JR; Kwong PD; Shapiro L
    PLoS Comput Biol; 2016 May; 12(5):e1004940. PubMed ID: 27191167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation.
    Johnson EL; Doria-Rose NA; Gorman J; Bhiman JN; Schramm CA; Vu AQ; Law WH; Zhang B; Bekker V; Abdool Karim SS; Ippolito GC; Morris L; Moore PL; Kwong PD; Mascola JR; Georgiou G
    Nat Commun; 2018 Oct; 9(1):4136. PubMed ID: 30297708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interrogation and mining of natively paired human V
    Wang B; DeKosky BJ; Timm MR; Lee J; Normandin E; Misasi J; Kong R; McDaniel JR; Delidakis G; Leigh KE; Niezold T; Choi CW; Viox EG; Fahad A; Cagigi A; Ploquin A; Leung K; Yang ES; Kong WP; Voss WN; Schmidt AG; Moody MA; Ambrozak DR; Henry AR; Laboune F; Ledgerwood JE; Graham BS; Connors M; Douek DC; Sullivan NJ; Ellington AD; Mascola JR; Georgiou G
    Nat Biotechnol; 2018 Feb; 36(2):152-155. PubMed ID: 29309060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody B cell responses in HIV-1 infection.
    Mouquet H
    Trends Immunol; 2014 Nov; 35(11):549-61. PubMed ID: 25240985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies.
    Kepler TB; Liao HX; Alam SM; Bhaskarabhatla R; Zhang R; Yandava C; Stewart S; Anasti K; Kelsoe G; Parks R; Lloyd KE; Stolarchuk C; Pritchett J; Solomon E; Friberg E; Morris L; Karim SS; Cohen MS; Walter E; Moody MA; Wu X; Altae-Tran HR; Georgiev IS; Kwong PD; Boyd SD; Fire AZ; Mascola JR; Haynes BF
    Cell Host Microbe; 2014 Sep; 16(3):304-13. PubMed ID: 25211073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-Pathogen Coevolution and the Emergence of Broadly Neutralizing Antibodies in Chronic Infections.
    Nourmohammad A; Otwinowski J; Plotkin JB
    PLoS Genet; 2016 Jul; 12(7):e1006171. PubMed ID: 27442127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?
    Parsons MS; Muller S; Kohler H; Grant MD; Bernard NF
    Hum Vaccin Immunother; 2013 Jul; 9(7):1532-8. PubMed ID: 23571168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.
    Scheepers C; Shrestha RK; Lambson BE; Jackson KJ; Wright IA; Naicker D; Goosen M; Berrie L; Ismail A; Garrett N; Abdool Karim Q; Abdool Karim SS; Moore PL; Travers SA; Morris L
    J Immunol; 2015 May; 194(9):4371-8. PubMed ID: 25825450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
    Walker LM; Burton DR
    Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.